Drug intelligence / Profile preview

SNT9465

Development stage
Phase 1
Lead developer
Syntara
Modality
Small Molecules
Administration
Topical
01

Overview

SNT9465 (also known as SNT-9465) is a topical, small molecule pan-lysyl oxidase (pan-LOX) inhibitor developed by Syntara Limited for the treatment of hypertrophic scarring. By inhibiting the lysyl oxidase enzyme family (LOX, LOXL1-4), the drug prevents the excessive cross-linking of collagen fibers that leads to the formation of thick, raised scars. SNT9465 is currently being investigated in a Phase 1b split-scar clinical trial in adults with hypertrophic sternotomy scars to evaluate its safety, target engagement, and efficacy in reducing scar severity. Syntara positions SNT9465 as a potential first-in-class pharmacological treatment for hypertrophic scarring, with plans to file an FDA Investigational New Drug (IND) application following Phase 1b results.

Other names
SNT9465SNT-9465SNT 9465
02

Targets

LOXL1 (Lysyl oxidase-like protein 1)LOXL3 (Lysyl oxidase-like protein 3)LOXL4 (Lysyl oxidase homolog 4)15-LOX (Lysyl Oxidase)

Beyond the preview

Go deeper on SNT9465.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNT9465.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call